6例集体重度氯气中毒患儿的多学科救治与护理

总结6例集体重度氯气中毒患儿的多学科救治与护理经验。包括成立多学科救护小组,实施肺通气保护策略,做好气道管理、眼部护理及有针对性的心理护理。通过专业的护理措施保证了重度氯气中毒患儿的治疗效果,6例患儿均痊愈出院。     

心血管病变对多囊卵巢综合征育龄妇女糖脂代谢、胰岛素抵抗及性激素的影响

目的探讨心血管病变对多囊卵巢综合征（PCOS）育龄妇女糖脂代谢、胰岛素抵抗及性激素的影响。方法选取80例PCOS病人为研究对象，均行血糖、胰岛素、血脂、性激素水平检查。根据是否合并心血管病变分为合并心血管病变组（n=17）和未合并心血管病变组（n=63），比较上述检查指标水平，并比较2组糖代谢异常、血脂异常、胰岛素抵抗（IR）、高雄激素血症（HA）发生率。结果合并心血管病变组较未合并心血管病变组餐后2 h血糖、空腹胰岛素、餐后2 h胰岛素、稳态模型胰岛素抵抗指数、总胆固醇、三酰甘油、低密度脂蛋白、睾酮、性激素结合蛋白水平均明显升高（P < 0.05~P < 0.01）。合并心血管疾病组糖代谢异常、IR、HA发生率均明显高于未合并心血管病变组（P < 0.05）。结论合并心血管病变的PCOS病人发生糖脂代谢异常、IR及HA的风险更大。     

铸造支架联合NITI悬臂梁矫正舌倾下颌磨牙的临床效果评价

目的 评价NITI悬臂梁在矫正舌倾下颌磨牙中的临床效果。方法 选择16例单侧下颌第二磨牙舌倾的病例为研究对象,带垫铸造支架连接双侧下颌后牙,提供颌内支抗、解除咬合锁结,0.018英寸×0.025英寸或0.019英寸×0.025英寸NITI悬臂梁提供颊向旋转力矩和压低力。采用Graphpad Prism 6.0 软件对治疗前、后所测数据进行配对 t 检验。结果 所有患牙均获得直立,牙轴变化24°±1.2°（P<0.01）,近中舌尖到正中矢状面垂直距离变化（3±0.8） mm（P<0.05）,牙周状况良好,咬合关系稳定。结论 铸造支架联合NITI 悬臂梁可提供有效力学机制,矫正舌倾下颌磨牙。     

医疗领域人工智能应用的研究进展＊

人工智能引发了医疗领域的数字革命，在推动行业发展方面具有极大潜力。本研究围绕临床诊疗、医学研究和公共卫生三个基本场景，聚焦人工智能与传统中医药的交叉与融合，并着重介绍人工智能在疾病诊断、决策支持、医学研究以及重大公共卫生事件中的应用。虽然人工智能在诸多方面显示出独特优势，但仍存在透明度不高、缺乏安全性评估和相关法律法规监管等问题需要谨慎解决，以促进人工智能技术在医疗领域的推广。     

Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter,randomized, open-label,phase 2 trial

We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).     

进食障碍患者家庭顺应量表的汉化及信效度检验

目的 汉化进食障碍患者家庭顺应量表，并检验其信效度。方法 根据Brislin翻译模式将量表翻译成中文，通过专家函询和预调查对量表进行文化调适和修订。将量表应用于300例进食障碍患者照顾者检验信效度。结果 中文版进食障碍患者家庭顺应量表的量表水平内容效度指数为0.918。探索性因子分析结果显示5个因子可解释总变异量的49.862%。量表的各维度得分与量表总分呈中高度相关，各维度得分之间呈中低度相关或不相关。量表总Cronbach′s α为0.877，重测信度为0.883。结论 中文版进食障碍患者家庭顺应量表具有较好的信效度，可用于测量进食障碍患者的家庭顺应情况。